Search
Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
(2020-07-07)
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The ...
Tractament de malalties minoritàries amb medicaments d'autorització individual a l'any 2019: informe d'avaluació de resultats
(2020)
Minority diseases pose a major challenge to the health system, as they are often of genetic origin and can affect many organs, be serious, pose a threat to life, or be chronically debilitating. Their diagnosis is difficult, ...
Tractament farmacològic de la malaltia d’Alzheimer: informe del Registre de Tractament Farmacològic de la Malaltia d’Alzheimer a l’any 2019
(2020)
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder that is usually slow but sustained over time. AD is the most common cause of dementia (69%). Its prevalence is 5.1% and increases exponentially ...
Àcid obeticòlic en combinació amb àcid ursodesoxicòlic (AUDC) per al tractament de la colangitis biliar primària que no respon adequadament a l’AUDC o en monoteràpia en adults que no toleren l’AUDC: informe d’avaluació de resultats
(2020-12)
Primary biliary cholangitis (CBP) is a chronic liver disease of autoimmune pathogenesis with a progressive clinical course that evolves over decades. It is characterized by a destruction of the intrahepatic bile ducts with ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC)
(2020-07-29)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...
Tractament del càncer colorectal metastàtic amb anticossos anti-VEGF o anti-EGFR en primera línia: informe d’avaluació de resultats
(2020)
Colorectal cancer (CRC) is the second most common cancer in the population as a whole and one of the leading causes of death in Europe. At the time of diagnosis, it is estimated that 25% of patients will metastasize and ...